Core Viewpoint - The approval of the clinical trial application for GenSci142 capsules marks the first successful application under the newly launched "30-day channel" for innovative drug clinical trial review and approval in China, indicating a significant step in enhancing the efficiency of drug development processes [2][5]. Company Summary - Changchun High-tech's subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (Jinsai Pharmaceutical), received approval from the National Medical Products Administration (NMPA) for the clinical trial of GenSci142 capsules, a first-class innovative biological product aimed at treating bacterial vaginosis, a common infection among women of childbearing age [2][4]. - GenSci142 capsules utilize bioinformatics and AI to optimize molecular structure, effectively targeting and destroying the main pathogens of bacterial vaginosis while preserving beneficial lactobacilli, thus addressing a significant unmet clinical need [4]. Industry Summary - The introduction of the "30-day channel" is part of a broader reform in China's drug review and approval system, which aims to enhance the efficiency of clinical trial management and promote drug innovation. The average review time for drug clinical trials has been reduced to approximately 50 working days since the implementation of the 60-day implied approval in 2019 [5][6]. - The new policy encourages global synchronized research and international multi-center clinical trials, which may attract multinational pharmaceutical companies to conduct early-stage research in China and support local researchers in leading international projects [7]. - The policy also emphasizes the development of pediatric and rare disease drugs, incentivizing companies to address gaps in these therapeutic areas and expedite access to urgently needed new medications for patients [7].

Core Viewpoint - Changchun Gaoxin's subsidiary, Jinsai Pharmaceutical, has received approval from the National Medical Products Administration for the clinical trial of GenSci142 capsules, a first-class innovative biological product aimed at treating bacterial vaginosis, addressing a significant unmet clinical need among women of childbearing age [1][4]. Group 1: Product Development - GenSci142 capsules are designed to selectively and rapidly kill the main pathogens of bacterial vaginosis while preserving protective lactobacilli, and they can penetrate and disrupt biofilms, reducing recurrence [4]. - The approval of the clinical trial for GenSci142 capsules marks the first new drug clinical trial application approved under the newly introduced "30-day channel" for innovative drug clinical trial reviews [5]. Group 2: Regulatory Environment - The National Medical Products Administration has optimized the clinical trial management system, significantly improving the efficiency of drug clinical trial reviews, with average review times reduced to about 50 working days [5]. - The new 30-day channel is designed for innovative drugs that meet specific criteria, including those with significant clinical value and those developed in sync with global research [6]. Group 3: Industry Impact - The policy changes are seen as a key measure for adapting pharmaceutical regulation to industry innovation, benefiting both large pharmaceutical companies and smaller innovative firms by enhancing the speed of clinical trial approvals [7]. - The encouragement of global synchronized research and international multi-center clinical trials is expected to attract multinational pharmaceutical companies to conduct early-stage research in China, integrating Chinese innovations into the global research framework [7].

Core Viewpoint - The National Medical Products Administration (NMPA) has officially launched a 30-day review and approval channel for innovative drug clinical trials, aimed at accelerating the drug development process in China [1][3]. Group 1: Overview of the 30-Day Channel - The 30-day channel for clinical trial applications is designed for innovative drugs that meet specific criteria, including traditional Chinese medicine, chemical drugs, and biological products [3][4]. - The introduction of the 30-day channel follows the implementation of a 60-day implied approval system in 2019, which significantly improved the efficiency of clinical trial reviews [3][8]. - The NMPA aims to enhance the speed of clinical trials while maintaining high safety standards, ensuring that the review process does not compromise the quality of drug safety assessments [9][10]. Group 2: Conditions for Eligibility - To qualify for the 30-day channel, drug applications must demonstrate significant clinical value and can include pediatric drugs, rare disease drugs, and traditional Chinese medicine [4][5]. - The channel encourages global synchronized research, requiring that Phase III international multi-center clinical trials be primarily led by Chinese clinical trial institutions [4][5]. - Applicants must commit to initiating clinical trials within 12 weeks of approval, which emphasizes the need for efficient clinical operations [6][8]. Group 3: Impact on the Industry - China's innovative drug development is rapidly advancing, with over 20% of the global pipeline of new drugs currently under research [8]. - In the first half of 2025, the total amount of innovative drug licensing reached nearly $66 billion, reflecting growing international recognition of Chinese innovative drugs [8]. - The NMPA's ongoing reforms in the review and approval system have led to a significant increase in the number of approved innovative drugs, with 43 approvals in the first half of the year, marking a 59% year-on-year increase [8][9].